PEG 3350 Market size was valued at USD 1.92 billion in 2023. The PEG 3350 Market industry is projected to grow from USD 2.08 Billion in 2024 to USD 3.71 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.63% during the forecast period (2024 - 2032). The rising prevalence of colon cancer in India and other developing nations, rising number of strategic initiatives, and increasing sedentary lifestyle and physical inactivity are driving market growth.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The prevalence of colon cancer is increasing worldwide. For instance, according to the article published by, lancet regional health Southeast Asia, colorectal cancer is the 7th most common cancer in India with 65,358 new cases in 2021. The incidence of colon cancer has been increasing worldwide and is currently 19.5 per 100,000 population globally and 15.2 per 100,000 population in India. Similarly, the changing lifestyles that include consumption of calorie-rich and low fibre diet, excessive use of red meat and processed foods, and physical inactivity. Also, the age-sex-adjusted rates of colon cancer in India have also raised by 20.6%, with a sharp increase in adults aged under 50 years.
Therefore, the rising number of colon cancers is likely to increase the demand for PEG 3350. This cumulative prevalence of colon cancer along with changing lifestyle habits such as rising consumption of alcohol and tobacco products, increasing rates of smoking, and poor dietary habits among the population are expected to drive the PEG 3350 markets during the forecast period.
The PEG 3350 Market segmentation, based on powder and bowel preparation kit. The powder segment held the majority share in 2022 in the PEG 3350 Market revenue. This is due to the several factors, such as growing sedentary lifestyles, physical inactivity, and the rising prevalence of colorectal cancer. The PEG 3500 powder, in combination with an electrolyte, is used before tests such as a colonoscopy and a barium enema X-ray exam. Moreover, worldwide, the powder for the solution has been widely prescribed by gastroenterologists and colorectal surgeons. As a result, there is a wide range of applications for treating constipation in various diseases as well prescribing with pharmaceutical drugs and giving them before medical tests to improve test results, drives segment growth.
Peg 3350 Market Size, By Product Type, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The PEG 3350 Market segmentation is based on age that includes pediatric, adult, and geriatric. The adult segment has dominated the market in 2022 and pediatric segment is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is attributed to the rising sedentary lifestyles & physical inactivity and an increasing prevalence of colorectal cancer among adults. Moreover, as per the American Society of Clinical Oncology, Middle-East and Africa Colorectal Cancer is increasing in younger adults and is most diagnosed in the US in both men and women. Therefore, several factors increase the chances of constipation and colorectal cancer among adults, and as per the FDA, PEG 3500 is effective among adults.
The PEG 3350 Market segmentation is based on application that includes constipation and medical tests. and surgery. The medical tests is further bifurcated into colonoscopy and barium enema x-ray examination. The constipation segment has dominated the market in 2022 and the medical tests segment is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is attributed to an increasing incidence of constipation among the worldwide population. According to the study, up to 85% of stroke patients may experience constipation. In October 2021, the World Health Organization estimated that 70% of strokes occur in low- and middle-income countries. As a result of the rising prevalence of constipation in the developing regions due to unhealthy lifestyles and the fact that patients with chronic diseases experience constipation, physicians & pharmacists are increasingly prescribing PEG 3500, fueling segment growth.
The PEG 3350 Market segmentation is based on distribution channels that includes online pharmacy, offline pharmacy. The offline pharmacy segment has dominated the market in 2022 and the online pharmacy segment is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to rising surgical procedures associated with the colon and rectum and other colon-related diseases that require medical tests. Moreover, according to several research studies, people in developing countries such as Algeria, Belarus, Nigeria, and Egypt lack access to online services. Approximately 90% of the population in these countries relies on offline pharmacies. Hence, the increasing number of surgical procedures is due to the increase in colon and rectal cancer, and underdeveloped countries heavily rely on offline pharmacies, further fueling segment growth.
March 2021: Pendopharm (Canada) launched Colyte Polyethylene Glycol 3350 and Electrolytes for Oral Solution is used to cleanse the colon (bowel) before certain medical tests (eg, colonoscopy, barium enema X-ray exam) or colon surgery.
By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America PEG 3350 market accounted for the largest market share in 2022. This is due to the rising prevalence of colorectal cancer and other diseases such as diabetes, cancer, and neurological disorders in the North American region. According to the American Cancer Society, there were 106,180 new cases of colon cancer and 44,850 new cases of rectal cancer in 2022 in America. Therefore, increasing prevalence of colon cancer further increases the chances of colorectal cancer surgery in North American region further increase the demand for PEG 3500, fueling the region's growth.
Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: Peg 3350 Market Size, By Region 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe PEG 3350 market accounts for the second-largest market share due to rising prevalence of colorectal cancer and increasing adoption of a sedentary lifestyle across the region. further, Germany PEG 3350 Market was attributed to hold the largest market share and is expected to fastest-growing market in the European region.
The Asia-Pacific PEG 3350 market is expected to grow at a significant share from 2024 to 2032. This is due to the rising geriatric population, adoption of sedentary lifestyles and physical inactivity, and the rising prevalence of colorectal cancer in the Asia-Pacific region. Moreover, China PEG 3350 Market is expected to hold the largest market share, and India PEG 3350 Market is expected fastest-growing market in the Asia-Pacific region.
Furthermore, In India, PEG 3500 demand is high among adults owing to chronic constipation. According to recent research, constipation is an emerging condition among Indians. Furthermore, researchers and scientists have found that the major cause of constipation in India is diet and lifestyle habits. Furthermore, the increasing colorectal cancer in the region, unhealthy diet and lifestyle habits and increasing colorectal cancer among the Indian population for the PEG 3350 market.
The Rest of the World is segmented into the Middle East, Africa, and Latin America. The PEG 3350 Market in the above-mentioned regions is likely to witness growth due to lack of awareness associated with the right diet. Moreover, as per the research, colorectal cancer is increasing in the Middle East in young and older adults and causes frequent constipation among children, further fueling the region's market growth.
PEG 3350 Key Market Players & Competitive Insights
The PEG 3350 Market is characterized by the presence of many global, regional, and local vendors. Developments in the healthcare industry and growing research and development make the PEG 3350 market lucrative. To expand their reach and optimize their operational costs, the major players focus on obtaining regulatory authorizations from government agencies for their products and emphasize acquisitions and product launches to gain a substantial market share. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Teva Pharmaceutical Industries Ltd (Israel), LGM Pharma (US), McKesson Corporation (US), and Sisco Research Laboratories Pvt. Ltd. (India) dominate the PEG 3350 Market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.
One of the primary business strategies adopted by manufacturers in the global PEG 3350 industry to benefit clients and expand the PEG 3350 market sector is to manufacture locally to reduce operating costs.
Bayer AG specializes in the development, manufacturing, and distribution of products in various industries such as nutrition, health care, and high-tech materials. The company operates through several segments, such as consumer health, pharmaceuticals, animal health, crop science, and Covestro. The pharmaceuticals segment is involved in the development, production, and marketing of prescription products for cardiology and women's health care, as well as in the production of diagnostic imaging tools and the necessary contrast agents, as well as in the development of specialized therapeutics for the treatment of oncology, hematology, and ophthalmology conditions. The company operates through a network of subsidiaries in Europe, Asia-Pacific, Latin America, North America, Africa, and the Middle East. For instance, in April 2018, The U.S Food and Drug Administration approved Bayer’s MiraLAX a Polyethylene Glycol 3350 medication drug to treat occasional constipation.
Also, LGM Pharma is one of the active pharmaceutical ingredient companies that offers API sourcing as well as drug product contract development and manufacturing solutions to the biotechnology, pharmaceutical, and compounding pharmacy industries. It has ISO 9001:2015 certification. The company has an unparalleled network of prequalified cGMP API manufacturers around the globe. It has US-based manufacturing and warehouse facilities and has delivered more than 6,000 APIs to its clients in the last three years.
Key Companies in the PEG 3350 Market include
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 1.92 billion |
| Market Size 2024 | USD 2.08 billion |
| Market Size 2032 | USD 3.71 billion |
| Compound Annual Growth Rate (CAGR) | 6.63% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2019 to 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Age, Application, and Distribution channel |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea. |
| Key Companies Profiled | Teva Pharmaceutical Industries Ltd (Israel), LGM Pharma (US), McKesson Corporation (US), Sisco Research Laboratories Pvt. Ltd. (India), BASF SE (Germany), Merck KGaA (US), Bayer AG (Germany), Lupin Pharmaceuticals, Inc (India), Breckenridge Pharmaceutical, Inc. (US), and Pendopharm (Canada) |
| Key Market Opportunities | ·      Entering developing markets |
| Key Market Dynamics | ·      Rising prevalence of colon cancer in India and other developing nations ·      Rising number of strategic initiatives ·      Increasing sedentary lifestyle and physical inactivity |
Frequently Asked Questions (FAQ) :
The PEG 3350 Market is anticipated to reach 3.09 billion at a CAGR of 6.63% during the forecast period of 2024-2032.
The US held over 93.66% share of the North America market for the PEG 3350 market during the forecast period of 2024-2032.
The PEG 3350 market is expected to grow at a 6.63% CAGR during the forecast period from 2024 to 2032.
The North American region market held the largest market share in the PEG 3350 Market.
The key players include Teva Pharmaceutical Industries Ltd (Israel), LGM Pharma (US), McKesson Corporation (US), Sisco Research Laboratories Pvt. Ltd. (India), BASF SE (Germany), Merck KGaA (US), Bayer AG (Germany), Lupin Pharmaceuticals, Inc (India), Breckenridge Pharmaceutical, Inc. (US), and Pendopharm (Canada).
The powder segment was estimated to lead the PEG 3350 Market.
The offline pharmacy segment is attributed to having the largest market share based on distribution channel.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
